A phase II study of clofarabine and daunorubicin in patients age 60 or older with newly diagnosed adult acute myeloid leukemia.

6602 Background: The outcome of acute myeloid leukemia (AML) patients (pts) ≥60 years (yrs) old remains poor, with a median overall survival of a few months. Neither the addition of other drugs dur...